Drug Trial Radar · NCT04739761
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
506
Actual
Start
Jun 22, 2021
Primary completion
Feb 8, 2024
Study completion May 26, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo
- First posted
- Feb 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is open-label, multicenter, international study, assessing the efficacy and safety of Trastuzumab deruxtecan (T-DXd) in participants with or without brain metastasis (BMs), with previously-treated advanced/metastatic HER2-positive breast cancer whose disease has progressed on prior anti-HER2-based regimens and who received no more than 2 lines/regimens of therapy in the metastatic setting (excluding tucatinib).
Conditions
- Breast Cancer
Interventions
Trastuzumab DeruxtecanDrug
Participants will receive T-DXd administered using an IV bag containing 5% (w/v) dextrose injection infusion solution.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) in Cohort 1 (Participants Without Brain Metastasis at Baseline)Time frame: From first dose (Day 1) to progression of disease (up to 2 years 7 months)
- Progression-free Survival (PFS) Rate at 12 Months in Cohort 2 (Participants With Brain Metastasis at Baseline)Time frame: At 12 months
Locations
81 sites in 18 countries. Site status is shown where the registry gives one.
Research Site
Boston, Massachusetts
Research Site
Durham, North Carolina
Research Site
Adelaide, Australia
Research Site
Auchenflower, Australia
Research Site
Clayton, Australia
Research Site
Heidelberg, Australia
Research Site
St Leonards, Australia
Research Site
Subiaco, Australia
Research Site
Anderlecht, Belgium
Research Site
Bruges, Belgium
Research Site
Leuven, Belgium
Research Site
Liège, Belgium
Research Site
Vancouver, British Columbia, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Copenhagen, Denmark
Research Site
Herlev, Denmark
Research Site
Odense C, Denmark
Research Site
Helsinki, Finland
Research Site
Tampere, Finland
Research Site
Turku, Finland
Research Site
Berlin, Germany
Research Site
Dresden, Germany
Research Site
Erlangen, Germany
Research Site
Essen, Germany
Research Site
Frankfurt, Germany
Research Site
Hamburg, Germany
Research Site
Hanover, Germany
Research Site
Kiel, Germany
Research Site
Mannheim, Germany
Research Site
München, Germany
Research Site
München, Germany
Research Site
Münster, Germany
Research Site
Tübingen, Germany
Research Site
Cork, Ireland
Research Site
Dublin, Ireland
Research Site
Dublin, Ireland
Research Site
Ancona, Italy
Research Site
Bergamo, Italy
Research Site
Catania, Italy
Research Site
Milan, Italy
Showing 40 of 81 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.